News

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during ...
Artelo Biosciences advances ART26.12 for psoriasis and CIPN, while ART27.13 shows early promise in cancer-related anorexia ...